Drugs / Chromium
Chromium
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04590534 | Aug 2020 → Feb 2023 | benign prostatic hyperplasia | Benha University | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06405243 | Jun → Dec 2024 | polycystic ovary syndrome | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT00145093 | Aug 2004 → Feb 2005 | type 2 diabetes mellitus | Medical Research Foundation, The Netherlands | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06709313 | Jun 2024 → Jan 2025 overdue | arthritis, sacroiliac, diabetes mellitus | Fayoum University | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04170439 | Nov 2019 → May 2020 | — | Aljazeera Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chromium | “garcinia 500 mg and chromium 281 mg” NCT04590534 ↗ |
| Known as | Biochrome | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201228 ↗ |
| Known as | Chromium, elemental | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201228 ↗ |
| Known as | Chromium, metallic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201228 ↗ |
| Known as | Dinakrome | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201228 ↗ |
| Modality | Small molecule | — CHEMBL1201228 ↗ |
| Route | Oral | “Patients are instructed to ingest 2 tablets of the study drug with breakfast and 2 with diner.” NCT00145093 ↗ |